Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Response and Adherence to Nilotinib in Daily Practice

Trial Profile

Response and Adherence to Nilotinib in Daily Practice

Phase of Trial: Phase IV

Latest Information Update: 10 Oct 2018

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms RAND
  • Most Recent Events

    • 03 Oct 2018 Status changed from recruiting to discontinued.
    • 25 Aug 2014 According to Netherlands Trial Registry record, Status changed from not yet recruiting to recruiting.
    • 28 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top